Afinity maturation and development of an anti-inflammatory monoclonal antibody [ 2009 - 2012 ]

Research Grant

Researchers: A/Pr Daniel Christ (Principal investigator)

Brief description Antibodies are a relatively new class of drugs that directly target molecular mechanisms of disease. Antibody therapies, such as the breast cancer drug Herceptin, have significantly increased our arsenal of effective therapeutics. In collaboration with G2 Therapies, we will use cutting-edge genetic engineering technology to produce fully human antibodies for the treatment of inflammatory diseases, such as rheumatoid arthritis.

Funding Amount $AUD 387,489.51

Funding Scheme Career Development Fellowships

Notes Industry CDF